Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $10.60

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been given a consensus recommendation of “Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $10.80.

A number of equities research analysts have commented on the stock. Piper Sandler lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday.

Insider Activity

In other news, Director Gautam Patel sold 17,410 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the sale, the director now owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. The trade was a 0.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 160,000 shares of company stock valued at $1,292,000 in the last 90 days. Company insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at $52,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Amneal Pharmaceuticals by 45.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company’s stock valued at $2,522,000 after buying an additional 99,866 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of Amneal Pharmaceuticals by 540.5% during the 4th quarter. Squarepoint Ops LLC now owns 124,744 shares of the company’s stock valued at $988,000 after buying an additional 105,268 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Amneal Pharmaceuticals by 97.9% during the 4th quarter. ProShare Advisors LLC now owns 59,493 shares of the company’s stock valued at $471,000 after buying an additional 29,424 shares in the last quarter. Finally, Quantedge Capital Pte Ltd purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at $598,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.9 %

NASDAQ:AMRX opened at $8.84 on Friday. Amneal Pharmaceuticals has a 12 month low of $5.18 and a 12 month high of $9.48. The company has a market cap of $2.74 billion, a PE ratio of -13.00 and a beta of 1.10. The company has a 50 day simple moving average of $8.14 and a two-hundred day simple moving average of $8.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same period last year, the firm posted $0.14 EPS. Research analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.